Abstract
Pyrazole scaffold containing compounds have been found to be as enzyme activator or inhibitor in the diabetic disease condition. The pyrazole containing compounds have been found to be activators in case such as glucokinase and as inhibitors in cases such as sodium glucose co-transporter-1, sodium-glucose co-transporter-2, dipeptidyl peptidase-4, glycogen synthase kinase-3beta, Glucagon-stimulated intracellular cAMP formation and 11β-HSD1. Pyrazole containing compounds can also act as competitive antagonist at cannabinoid-1 receptor while agonist at peroxisome proliferatoractivated receptor-α and γ. In present work, the most active pyrazole derivatives have been selected from reported literature along with methods utilized for detection of blood plasma glucose levels or urinary glucose levels as well as assays involving enzyme inhibition or activation at cellular level. The activity values of corresponding pyrazole compounds obtained from synthetic or structural activity relationship studies can be helpful for medicinal chemist to focus design of novel chemical entities containing pyrazole system as a part of antidiabetic drug substance.
Keywords: Pyrazole, antidiabetic, Sodium glucose co- transporter, Peroxisome proliferator-activated receptor, Glycogen synthase kinase, Dipeptidyl peptidase-4.
Letters in Drug Design & Discovery
Title:Development of Pyrazole Compounds as Antidiabetic Agent: A Review
Volume: 11 Issue: 5
Author(s): Prasanna A. Datar and Sonali R. Jadhav
Affiliation:
Keywords: Pyrazole, antidiabetic, Sodium glucose co- transporter, Peroxisome proliferator-activated receptor, Glycogen synthase kinase, Dipeptidyl peptidase-4.
Abstract: Pyrazole scaffold containing compounds have been found to be as enzyme activator or inhibitor in the diabetic disease condition. The pyrazole containing compounds have been found to be activators in case such as glucokinase and as inhibitors in cases such as sodium glucose co-transporter-1, sodium-glucose co-transporter-2, dipeptidyl peptidase-4, glycogen synthase kinase-3beta, Glucagon-stimulated intracellular cAMP formation and 11β-HSD1. Pyrazole containing compounds can also act as competitive antagonist at cannabinoid-1 receptor while agonist at peroxisome proliferatoractivated receptor-α and γ. In present work, the most active pyrazole derivatives have been selected from reported literature along with methods utilized for detection of blood plasma glucose levels or urinary glucose levels as well as assays involving enzyme inhibition or activation at cellular level. The activity values of corresponding pyrazole compounds obtained from synthetic or structural activity relationship studies can be helpful for medicinal chemist to focus design of novel chemical entities containing pyrazole system as a part of antidiabetic drug substance.
Export Options
About this article
Cite this article as:
Datar A. Prasanna and Jadhav R. Sonali, Development of Pyrazole Compounds as Antidiabetic Agent: A Review, Letters in Drug Design & Discovery 2014; 11 (5) . https://dx.doi.org/10.2174/1570180810666131113212354
DOI https://dx.doi.org/10.2174/1570180810666131113212354 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medicinal Plants for Diabetes Treatment During Pregnancy
Current Medicinal Chemistry The Complications of Bariatric Surgery Patients with Type 2 Diabetes in the World: A Systematic Review and Meta-Analysis
Current Diabetes Reviews Epidemiology of Type 1 Diabetes in Latin America
Current Diabetes Reviews Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Role of NFAT5 in Inflammatory Disorders Associated with Osmotic Stress
Current Genomics Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Pregnancy: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics The Impact of a New Best Practice Advisory on the Management of Diabetic Ketoacidosis
Current Diabetes Reviews Diabetes in Racial and Ethnic Minorities in the United States: Individualizing Approaches to Diagnosis and Management
Current Diabetes Reviews Neonatal Diabetes: Applying Molecular Biology to Patient Care
Current Pediatric Reviews Risks Associated with SGLT2 Inhibitors: An Overview
Current Drug Safety Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design The Impact of Oxidative Stress on Islet Transplantation and Monitoring the Graft Survival by Non-Invasive Imaging
Current Medicinal Chemistry Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Current Diabetes Reviews Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Neuroinflammation, Diabetes and COVID-19: Perspectives Coming from Ca<sup>2+</sup>/cAMP Signalling
Current Drug Research Reviews COVID-19 in People with Diabetes: Epidemiological Perspectives and Public Health Actions in the Middle East and North Africa (MENA) Region
Current Diabetes Reviews Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Decreased Plasma Level of Lipoprotein Lipase Predicted Verbal Disfluency in Chinese Type 2 Diabetes Mellitus Patients with Early Cognitive Deficits
Current Alzheimer Research